Trag-3

• Background:

  The expression of the cancer-testis antigen Taxol resistance-associated gene-3 (TRAG-3) is associated with acquired paclitaxel (Taxol) resistance, and is expressed in a variety of cancers - e.g., breast cancer, leukemia, and melanoma. Overexpressed in taxol-resistant breast cancer line MDA 435(TR) and the doxorubicin-resistant multiple myelanoma lines 8226/Dox(40) and 8226/MDR(10)V. Weakly expressed in kidney. TRAG-3 is an attractive target for immunotherapy of cancer._x000B__x000B_First identified as a novel cancer/testis antigen, TRAG-3, (Taxol Resistance Associated Gene-3) was initially discovered in a search for new genes involved in drug resistance. Early studies of TRAG-3 revealed a minimal to absent expression in normal tissues and a marked over-expression in many carcinoma cell lines including several melanoma lines. By RT-PCR evaluation of TRAG-3 two transcripts are seen in many carcinoma cell lines with products in the the 799 bp and a second alternatively spliced transcript._x000B_

• Synonyms:

  Taxol resistance-associated gene-3

• Conjugation:

  Unconjugated

• Type:

  Blocking Peptide

• Applications:

  Functional Inhibition

• Assay Principle:

  Blocking peptide for use with Trag-3 antibodies (Cat. Nos. X1871P , X1872P).

• Stability:

  See expiration date on vial

• Concentration:

  See vial for Concentration

• Form:

  Provided as solution in phosphate buffered saline with 0,08% sodium azide

• Precautions:

  This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving Humans or animals.

• Shipping Conditions:

  Ambient Temperature, freeze upon arrival

• Storage Conditions:

  Product should be stored at -20ºC; Aliquot to avoid freeze/thaw cycles

• Functional Analysis:

  Antibody Function Blocking